Objective To observe the clinical efficacy of sacubitril vasartan in the treatment of Heart Failure Patients with Reduced ejection fraction(HFrEF). Methods A total of 62 patients diagnosed with HFrEF in our hospital from November 2018 to October 2020 were selected as the observation objects.They were randomly divided into observation group and control group,with 31 cases in each group.On the basis of anti-heart failure treatmen,the observation group was treated with Sacubitril Valsartan,the control group was treated with Benazepril Hydrochloride. Observed the clinical efficacy and occurrence of adverse reactions, the heart failure related indicators before and after treatment were compared between the two groups. Results After treatment, the total effective rate of the observation group was higher than the control group, and the difference was statistically significant (P＜0.05), the incidence of adverse reactions of the observation group had no statistically significant compared with the control group (P＞0.05). After treatment,the heart failure related indicators of the tow groups were improved than before treatment(P＜0.05),and the observation group was better than the control group(P＜0.05). Conclusion Sacubitril Valsartan is superior to Benazepril Hydrochloride in the treatment of HFrEF patient.It can significantly improve the cardiac function and delay ventricular remodeling.In addition,the safety is higher.
万方数据